Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors

Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892-1101, USA.
Cancer Chemotherapy and Pharmacology (Impact Factor: 2.77). 09/2010; 66(4):737-43. DOI: 10.1007/s00280-009-1218-z
Source: PubMed


To describe the pharmacokinetics of orally administered ABT-751 and its conjugated metabolites in children with neuroblastoma and other solid tumors and to relate pharmacokinetic parameters to toxicity and therapeutic outcomes.
Patients (median age, 11 years) with neuroblastoma (n = 37) or other solid tumors (n = 25) had pharmacokinetic sampling after the first dose of ABT-751 (75-250 mg/m(2)/day) on a 7-day or 21-day schedule. ABT-751 and its glucuronide and sulfate metabolites were quantified with an HPLC/MS/MS assay. Pharmacokinetic parameters were derived with non-compartmental methods. The relative bioavailability of more water soluble capsule and suspension formulations was assessed.
ABT-751 peaked in plasma at 2 h and declined monoexponentially with a t (1/2) of 5.1 h. The apparent clearance was 33 ml/min/m(2) and was age-independent. The AUC(0-infinity) increased in proportion to the dose, and at 200 mg/m(2) the median AUC(0-infinity) was 91 mcg h/ml and the C (ave) was 3.9 mcg/ml. Inter-and intra-patient variability was low. The metabolites were detected in plasma 30 min post-dose and peaked 3-5 h after the dose. The glucuronide:sulfate molar AUC(0-infinity) ratio was 0.57. Less than 1% of the dose was excreted in urine as parent drug; 13% of the dose was excreted as sulfate metabolite and 10% as glucuronide metabolite. The relative bioavailability of the water soluble capsule and suspension formulations was 105 and 93%, respectively. AUC(0-infinity) was higher in patients experiencing dose-limiting toxicity.
Oral ABT-751 pharmacokinetics was dose-proportional and age-independent with minimal intra- and inter-patient variability in children.

8 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Relapsed acute lymphoblastic leukemia (ALL) represents a major cause of morbidity and mortality in pediatrics. With contemporary chemotherapy, >85% of patients with newly diagnosed ALL survive. Unfortunately, 20% of these patients will relapse and for these children, outcomes remain poor despite our best known chemotherapy protocols. Most of these children will achieve a second complete remission, but maintaining this remission remains difficult. Because relapsed ALL is such a significant cause of morbidity and mortality, it is the focus of much research interest. Efforts have been made and continue to focus on understanding the underlying biology that drives relapse. The role of hematopoietic stem cell transplantation in relapsed ALL remains unclear, but many clinicians still favor this for high-risk patients given the poor prognosis with current chemotherapy alone. It is important to use new drugs with little cross-resistance in the treatment of relapsed ALL. New classes of agents are currently being studied. We also discuss prognostic factors and the biology of relapsed ALL.
    No preview · Article · Dec 2012 · Paediatric Drugs
  • [Show abstract] [Hide abstract]
    ABSTRACT: Today's data acquisition and control system designers are being challenged by ever-increasing channel counts, higher scan rates end the demand for faster real-time performance in the systems that they must configure. To meet these needs, KineticSystems Corporation has derived the Reality software package through technology transfer from the Department of Energy. This paper describes the open client/server architecture of the Reality software package. The host software runs on UNIX-based workstations end communicates with the I/O chassis using TCP/IP protocol. The key to the high I/O performance is the use of VxWorks<sup>(TM</sup>), a rest-time kernel, in the controller for each I/O chassis. Also described is how this software includes intelligent data acquisition as well as real-time display, analysis and control. In order to provide the high transfer rates needed for the acquired data from a number of VXI I/O chassis to a hard disk, this software can be combined with a high-speed fiber-optic interconnect. This paper also describes two large applications where this software is being employed. They include the monitoring of static end dynamic data from large wind tunnels and the testing of rocket motors. Additionally, this software fulfils the Department of Defense directive to use COTS (commercial-off-the-shelf) products, based on recognized standards, whenever possible. Also discussed is the quite positive experience with technology transfer and the benefits derived by the US Government as well as by the commercial marketplace
    No preview · Conference Paper · Oct 1996
  • [Show abstract] [Hide abstract]
    ABSTRACT: Combretastatin A4 phosphate (CA4P) is the lead compound of a relatively new class of agents termed vascular disrupting agents that target existing tumor blood vessels. Rapid tumor blood flow shutdown has been demonstrated in preclinical models and patients by various techniques such as dynamic contrast-enhanced MRI, perfusion computed tomography and PET scans following CA4P infusion. CA4P typically induces rapid tumor necrosis in the center of the tumor and leaves a rim of viable cells in the periphery. In oncology, CA4P does not appear to be that active by itself, but may be more efficacious when combined with chemotherapy, antiangiogenic therapy and radiation therapy. Studies are currently underway, which combine CA4P with antiangiogenic agents. Side effects have included hypertension, tumor pain and occasional cardiovascular toxicity, without any significant myelosuppression or disabling systemic symptoms. The utility of CA4P for conditions other than cancer, which involves neovascularization such as macular degeneration, is also being explored.
    No preview · Article · Aug 2010 · Future Oncology
Show more